Awaiting product image

Medical Imaging Markets, Volume V – Molecular Imaging

$2,995.00 – $5,990.00

SKU: KLI1350449 Categories: , Pages: 136

Description

Molecular imaging maps the locations of specific molecules and biomaterials within living tissue. As such, it has the potential to diagnose a disease, to monitor the course of that disease, and possibly facilitate treatment. Molecular imaging has developed into a promising new strategy for the diagnosis, evaluation and treatment of disease.

The final volume in Kalorama’s Medical Imaging Markets series: Medical Imaging Markets, Volume V, Molecular Imaging offers complete market coverage of world markets for molecular imaging products for the following technologies:

  • PET
  • SPECT-Gamma Camera Systems
  • MRI
  • CT
  • Ultrasound
  • Fusion Imaging
  • Optical Imaging

Interest in and use of the technology has exploded in recent years, thanks to advances in cell biology, biochemical agents, and computer analysis, and serious market watchers in medical imaging industries, as well as those serving or investing in medical imaging companies, will want to keep abreast of this new market. As part of its comprehensive coverage, Medical Imaging Markets, Volume V, Molecular Imaging includes:

  • Complete Overview and Explanation of modalities and key applications
  • Over 35 Figures and Tables to make market data accessible to users.
  • Review of Imaging Agents in Clinical Trials, or that are recently introduced.
  • Market Size and Forecasts are developed through 2011.
  • Profiles of Top Competitors in the industry including: including Gamma Medica, GE Healthcare, Hiatchi, OptoSonics, Philips, Siemens and Toshiba, among others.

Kalorama looks at the technologies currently used in molecular imaging but also examines novel research areas, such as:

  • PET Targets Alzheimer’s Disease
  • Rubidium-based PET
  • PET Diagnoses Pancreas Defects
  • Hyper-Cest MRI
  • Molecular Breast Imaging
  • Drug Abuse
  • Radiotracers and Drug Addiction
  • Whole-Body PET
  • PET/CT for Ovarian Cancer
  • SPECT for Lower Back Pain
  • Contrast-Enhanced Ultrasound

As part of Kalorama’s trusted information-gathering process, the information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence with medical imaging company executives were the primary method of gathering information and developing forecasts.

Table of Contents

Chapter One: Executive Summary

  • 1.1 Molecular Basis of Cell Function
  • 1.2 Driving Healthcare
  • 1.3 Two Components
  • 1.4 Key Modalities
  • 1.5 World Market Summary
  • 1.5.1 Market Drivers and Challenges
  • 1.5.2 Growth Analysis
  • 1.6 Methodology

Chapter Two: Introduction

  • 2.1 Background and Definitions
    • 2.1.1 Nuclear Medicine
    • 2.1.2 Imaging Agents and Traditional Anatomic Modalities
  • 2.2 New Direction for Medicine
  • 2.3 Modalities and Applications
    • 2.3.1 Nuclear Medicine
    • 2.3.1.1 Positron Emission Tomography (PET)
    • 2.3.1.2 Single Photon Emission Computed Tomography (SPECT) and Gamma Cameras
    • 2.3.2 Computed Tomography (CT)
    • 2.3.3 Magnetic Resonance Imaging (MRI)
    • 2.3.4 Ultrasound
    • 2.3.5 Fusion Imaging
    • 2.3.5.1 PET/CT
    • 2.3.5.2 SPECT/CT
    • 2.3.6 Optical Imaging, Near Infrared (NIR)
  • 2.4 Drivers
  • 2.5 Issues and Challenges
    • 2.5.1 Imaging Agent Delivery and Observation
    • 2.5.2 SPECT/CT and Targeted Imaging
    • 2.5.3 Optical Technology
    • 2.5.4 Application-Specific Controversies

Chapter Three: Promising Research

  • 3.1 PET Targets Alzheimer’s Disease
  • 3.2 Rubidium-Based PET
  • 3.3 PET Diagnoses Pancreas Defects
  • 3.4 Hyper-Cest MRI
  • 3.5 Molecular Breast Imaging
  • 3.6 Drug Abuse
  • 3.7 Radiotracers and Drug Addiction
  • 3.8 Whole-Body PET
  • 3.9 PET/CT for Ovarian Cancer
  • 3.10 SPECT for Lower Back Pain
  • 3.11 Contrast-Enhanced Ultrasound
  • 3.12 Preclinical Drug Research

Chapter Four: Markets

  • 4.1 Overview
  • 4.2 Procedures
  • 4.3 Market Forecasts
    • 4.3.1 PET
    • 4.3.2 SPECT-Gamma Camera Systems
    • 4.3.3 Molecular Magnetic Resonance Imaging (MRI)
    • 4.3.4 Molecular Computed Tomography (CT)
    • 4.3.5 Ultrasound
    • 4.3.6 Fusion Imaging
    • 4.3.7 Optical Imaging
  • Chapter Five: Corporate Profiles
    • 5.1 Agilent Technologies
    • 5.2 Bioscan
    • 5.3 Capintec Inc.
    • 5.4 Digirad Corp
    • 5.5 Gamma Medica Inc
    • 5.6 GE Healthcare
    • 5.7 Hitachi Medical Systems America Inc.
    • 5.8 IS2 Medical Systems
    • 5.9 MIR Preclinical Services
    • 5.10 OptoSonics Inc.
    • 5.11 Philips Medical Systems
    • 5.12 Positron Corp.
    • 5.12 Positron Corp.
    • 5.13 Siemens Medical Solutions
    • 5.14 Spectrum Dynamics Ltd.
    • 5.15 Toshiba America Medical Systems
    • 5.16 UltraSPECT Ltd.
    • 5.17 VisEn Medical Inc.
    • 5.18 Zecotek Medical Systems
  • list of exhibits
  • Chapter One: Executive Summary
    • Exhibit 1 Market Summary: World Market for Molecular Imaging 2007-2011
  • Chapter Two: Introduction
    • Exhibit 2: Key Liquid Radionuclides
  • Chapter Four: Markets
    • Exhibit 3: Worldwide Distribution of SPECT Procedures by Specialty 2006
    • Exhibit 4: U.S. Distribution of SPECT Procedures by Specialty 2006
    • Exhibit 5: Worldwide Distribution of PET Procedures by Specialty 2006
    • Exhibit 6: U.S. Distribution of PET Procedures by Specialty 2006
    • Exhibit 7: Worldwide Geographic Distribution of Molecular CT Procedures by Region (U.S., Europe, ROW) 2006
    • Exhibit 8: Worldwide Geographic Distribution of Molecular MRI Procedures by Region (U.S., Europe, ROW) 2006
    • Exhibit 9: World Medical Market for PET Systems Dollar Volume 2007-2011
    • Exhibit 10: U.S. Medical Market for PET Systems Dollar Volume 2007-2011
    • Exhibit 11: World Medical Market for PET Systems Unit Sales 2007-2011
    • Exhibit 12: U.S. Medical Market for PET Systems Unit Sales 2007-2011
    • Exhibit 13: World Medical PET Systems Estimated Installed Base by Region (U.S. vs Non-U.S.) 2006
    • Exhibit 14: World Medical Market for SPECT Systems Dollar Volume 2007-2011
    • Exhibit 15: U.S. Medical Market for SPECT Systems Dollar Volume 2007-2011
    • Exhibit 16: World Medical Market for SPECT Systems Unit Sales 2007-2011
    • Exhibit 17: U.S. Medical Market for SPECT Systems Unit Sales 2007-2011
    • Exhibit 18: World Medical SPECT Systems Estimated Installed Base by Region (U.S. vs Non-U.S.) 2006
    • Exhibit 19: World Medical Market for Molecular MRI Systems Dollar Volume 2007-2011
    • Exhibit 20: U.S. Medical Market for Molecular MRI Systems Dollar Volume 2007-2011
    • Exhibit 21: World Medical Market for Molecular CT Systems Dollar Volume 2007-2011
    • Exhibit 22: U.S. Medical Market for Molecular CT Systems Dollar Volume 2007-2011
    • Exhibit 23: World Medical Market for Molecular Ultrasound Systems Dollar Volume 2007-2011
    • Exhibit 24: U.S. Medical Market for Molecular Ultrasound Systems Dollar Volume 2007-2011
    • Exhibit 25: World Medical Market for Molecular PET/CT 2007-2011
    • Exhibit 26: U.S. Medical Market for Molecular PET/CT 2007-2011
    • Exhibit 27: World Medical Market for Molecular SPECT/CT 2007-2011
    • Exhibit 28: U.S. Medical Market for Molecular SPECT/CT 2007-2011
    • Exhibit 29: World Market for Molecular Imaging by Modality (PET, SPECT, CT, MRI, Ultrasound, PET/CT) 2007, 2009, 2011

 

Related products

Drug Delivery Series I-IV (Oral, Implantable/Injectable, Pulmonary and Transdermal/Transmucosal...U.S. Market for Home Care Products, 5th Edition